Introduction: the challenge of recurrence

Leiomyosarcoma (LMS) is a rare and aggressive cancer that develops in smooth muscle tissue, found in areas like the uterus, abdomen, and blood vessels.^1,2 Treatments such as surgery, chemotherapy, and radiotherapy can be effective at removing or shrinking the initial tumour, but LMS can come back, sometimes years after treatment ends.^3,11

This return, known as recurrence, is a major concern for many patients and families. Understanding when recurrence is most likely, why it happens, and how to manage the risk helps individuals feel more informed and empowered. This article explores the timing of LMS recurrence, risk factors, the importance of monitoring, and how to access ongoing support.^4,6,10

What does "recurrence" mean in leiomyosarcoma?

Hearing that LMS may return can be frightening. Recurrence means some cancer cells remained in the body after treatment – even when scans showed no evidence of disease – and have grown again into a detectable tumour.^{4, 6}

There are three main types of recurrence:

• Local recurrence: Cancer returns near the original tumour site, affecting nearby tissue or muscle^{6, 9}
• Regional recurrence: In some cases, the cancer may reappear in the lymph nodes located close to where the tumour developed initially. Though uncommon in LMS, this form of recurrence still requires ongoing medical attention⁴
• Distant recurrence (metastasis): This involves the cancer travelling to other parts of the body, such as the lungs, liver, or bones, which is more common in LMS and can be more serious^6,7,12

Each type of recurrence is managed differently, depending on its location and extent, to ensure the most effective treatment strategy is used.⁶

The critical time window: when does recurrence typically happen?

After their initial treatment, many people may ask: when is the risk of LMS recurrence at its highest? While LMS doesn’t follow a fixed schedule, certain patterns help guide follow-up plans.

The highest risk period is generally within the first two to three years after treatment.^5,6 That’s why more frequent imaging and appointments are recommended during this time,  to catch any recurrence as early as possible.^6,8

Doctors may refer to “median recurrence-free survival”, which is the point when half of the patients have experienced recurrence, and the other half have not. For higher-risk LMS cases, this can occur between 12– 24 months post-treatment.^5,6

However, recurrence can still happen many years later – even after five, ten, or more years.^4,6 That’s why long-term, sometimes lifelong, monitoring is important. This reinforces the importance of long-term vigilance – not to raise anxiety but to support proactive health planning.

Follow-up visits usually begin every few months and gradually become less frequent if no recurrence is found.^6,8 Even if you're feeling well, staying in contact with your medical team remains important.

Predictors: what factors influence the risk of recurrence?

While exact predictions are difficult, doctors assess multiple tumour characteristics and treatment-related elements to estimate risk and guide follow-up:

• Tumour grade: High-grade leiomyosarcomas tend to grow faster and are more prone to coming back after treatment^3,6,12
• Size: Tumours larger than 5 cm tend to carry a higher risk, often because they are harder to remove fully^4,6,9
• Location:
  • Site affects behaviour: When LMS begins in the uterus, it might progress differently or show distinct recurrence trends compared to tumours that develop in the abdomen or limbs^6,10,14,15
  • Retroperitoneal tumours are often difficult to remove completely during surgery due to their location near vital organs^10,14
• Stage at diagnosis: Advanced-stage LMS increases the chance of recurrence^4,6,7

Treatment factors also matter

• Surgical margins: If the tumour was not fully removed (positive margins), the recurrence risk increases^{6, 12, 14}
• Adjuvant therapy: Chemotherapy or radiotherapy after surgery can reduce recurrence risk in high-risk patients^{8, 13}
• Patient Factors: Age and general health affect treatment choices but do not directly alter recurrence risk^{4, 13}

Recognising these risk factors helps healthcare providers tailor follow-up care and choose treatments that are best suited to everyone.

Staying on track: checking for cancer’s return

After initial treatment for LMS, managing the risk of recurrence becomes part of long-term care. While anxiety is normal, proactive steps like consistent check-ups and body awareness significantly improve chances of early detection.^{4, 6}

Why vigilant follow-up matters

Medical monitoring after LMS treatment is clinically essential. Since most recurrences emerge within 2–3 years, early surveillance involves frequent physical examinations and imaging scans such as CT, MRI, or PET.^{4, 6, 10} These methods can detect subtle cancer returns often before symptoms appear. Scheduling adapts to your tumour’s profile:

• Early phase: Initially, follow-up visits may be scheduled every few months to monitor your recovery closely⁴
• Long-term: Annual checks or more frequent monitoring, as late recurrence remains possible^{5, 9}

Body awareness between visits

Your self-observations are critical. Keep an eye on  your baseline health and let your clinician know of any:

• New pain or unusual lumps
• Persistent coughing or swelling
• Unexplained weight loss or fatigue

Report any new symptoms as soon as you notice them, even if your next scan is not due yet.^{6, 10}

Impact of timely detection

Early identification of recurrence often expands treatment options and improves disease control potential. While not all recurrences are curable, catching them when they are smaller or localised enhances management success.^4,6,14

Living with LMS requires ongoing vigilance, but should not dominate your life. Through consistent monitoring, awareness of bodily changes, and clear communication with your healthcare team, you can actively safeguard your health. Support resources remain available to help navigate this journey with greater confidence.⁵

Facing recurrence: options and outlook

A cancer recurrence can feel disheartening, but it does not mean hope is lost. Many people continue to lead fulfilling lives thanks to advancing treatments and supportive care.^{5, 9}

Understanding treatment options

Treatment after recurrence is personalised. Your care team will consider where the cancer has returned, how much it has spread, your previous treatments and overall health.⁵ If the recurrence is localised, surgery may still be an option. In other cases, radiotherapy or chemotherapy might help to slow progression, ease symptoms, or shrink tumours.^{5, 6}

Considering clinical trials

Some patients may be eligible for clinical trials, which offer access to emerging treatments not yet widely available. Trials are carefully regulated studies that aim to improve future care while offering possible benefits to participants.¹² Your healthcare provider will consider your circumstances to guide you toward the most appropriate options.⁵

Emotional support and coping

Facing a recurrence can bring feelings of fear, sadness, or uncertainty. These emotions are valid. Talking to your medical team, joining a sarcoma support group, or speaking with a therapist may help you regain a sense of control and well-being.^5,13

Staying involved in your care

Good communication is key. Ask questions about the goals of your treatment—whether it's to reduce tumour size, relieve symptoms, or maintain quality of life. Understanding what to expect can help you take an active role in your care decisions.^5,11

The road ahead: research and hope

Scientists continue to explore why leiomyosarcoma (LMS) recurs and how to prevent it. Advances in molecular profiling, targeted therapies, and immunotherapy are creating new treatment possibilities tailored to individual tumour characteristics.^3,12 Researchers are also investigating biomarkers that might help predict recurrence earlier or guide future care decisions.

Clinical trials drive this scientific advancement. These studies give patients access to innovative treatments while helping to improve outcomes for others in the future.^2,13 Even when facing recurrence, many people find hope in knowing that research is actively shaping better options for tomorrow.

Summary

• LMS recurrence is most likely in the first 2–3 years after treatment, but long-term monitoring is important
• Factors like tumour grade, size, stage, and surgical margins influence individual risk^{1, 5}
• Regular follow-up scans and check-ups are essential, often continuing for life⁴
• Contact your medical team if you notice new symptoms—do not wait for scheduled appointments⁶
• A variety of treatment options exist, including surgery, radiotherapy, chemotherapy, and emerging therapies¹¹
• Emotional and peer support can help you stay informed, resilient, and connected throughout the journey⁷